Table 2.

Summary statistics for change from baseline of QTcF interval (pharmacodynamic analysis set)

Cycle	Days	Time point	N	Mean (SD) ms	Median ms	Min:Max Ms	Q1:Q3 ms	90 % CI ms
1	1	Predose	31	1.7 (15.5)	−0.3	−30.3:45.7	−8.3:8.0	−3.0:6.4
		0.5	32	2.3 (10.1)	2.7	−25.3:23.0	−5.2:9.5	−0.8:5.3
		1	32	−0.5 (11.4)	−2.0	−18.0:27.7	−9.7:4.8	−4.0:2.9
		1.5	32	0.2 (14.3)	−0.3	−23.7:27.7	−10.7:11.3	−4.1:4.5
		2	32	−1.7 (10.0)	−2.0	−20.0:19.0	−8.5:5.3	−4.6:1.3
		3	31	−2.9 (12.0)	−5.3	−24.3:20.7	−12.7:5.7	−6.5:0.8
		4	31	−3.0 (8.0)	−1.0	−20.3:11.7	−7.3:2.3	−5.4:−0.6
		6	31	1.4 (13.0)	1.0	−35.0:21.7	−7.7:14.7	−2.5:5.4
		8	32	−1.4 (13.1)	−1.3	−44.0:22.7	−9.3:6.2	−5.3:2.5
		12	31	0.3 (11.9)	4.0	−37.7:22.0	−7.0:6.7	−3.4:3.9
		24	28	−6.0 (9.7)	−5.2	−37.0:6.7	−8.5:−1.2	−9.1:−2.9
2	1	Predose	29	−3.4 (13.2)	−3.3	−38.7:18.3	−13.3:6.7	−7.6:0.8
		0.5	32	−3.1 (11.8)	−3.2	−32.0:18.3	−9.7:5.7	−6.6:0.5
		1	33	−1.7 (13.9)	0.0	−31.7:20.3	−11.3:9.0	−5.8:2.4
		1.5	33	−4.2 (15.6)	−1.0	−37.7:34.0	−13.7:4.0	−8.8:0.4
		2	33	−4.7 (12.1)	−3.3	−27.0:19.7	−14.0:4.0	−8.3:−1.1
		3	33	−5.0 (15.4)	−2.0	−42.0:19.0	−15.7:7.3	−9.6:−0.5
		4	32	−6.2 (14.4)	−5.3	−30.3:28.7	−17.7:3.3	−10.5:−1.9
		6	30	−3.1 (17.6)	−6.2	−42.0:27.0	−12.0:9.3	−8.6:2.4
		8	32	−3.1 (16.0)	−6.2	−37.0:35.7	−12.5:7.7	−7.9:1.7
		12	33	−2.9 (11.2)	−4.7	−21.7:23.3	−9.0:4.3	−6.2:0.4
		24	29	−11.9 (14.2)	−12.7	−38.0:21.7	−20.7:−3.7	−16.4:−7.4